2018年3月
Dose-finding and efficacy confirmation trial of the superselective intra-arterial infusion of cisplatin and concomitant radiotherapy for locally advanced maxillary sinus cancer (Japan Clinical Oncology Group 1212): Dose-finding phase
Head and Neck
- 巻
- 40
- 号
- 3
- 開始ページ
- 475
- 終了ページ
- 484
- 記述言語
- 掲載種別
- 研究論文(学術雑誌)
- DOI
- 10.1002/hed.25001
© 2017 Wiley Periodicals, Inc. Background: We are currently undertaking a multi-institutional prospective trial of the superselective intra-arterial infusion of high-dose cisplatin with concomitant radiotherapy for patients with T4aN0M0 or T4bN0M0 locally advanced maxillary sinus squamous cell carcinomas (SCC). We herein report the results of the dose-finding phase. Methods: The dose-finding phase sought to evaluate the incidence of dose-limiting toxicities and determine the recommended number of cycles of the intra-arterial infusion of cisplatin. In this phase, 100 mg/m2 of cisplatin was administered intra-arterially weekly for 7 weeks with concomitant radiotherapy (70 Gy). Results: All 18 patients received a full dose of radiotherapy. The number of cycles of cisplatin was 7 in 13 patients and 6 in 5 patients. The dose-limiting toxicities were observed in 5 patients. Conclusion: These results indicated that this therapy is safe and well-tolerated at 7 cycles of cisplatin, which was determined to be the recommended number of cycles for locally advanced maxillary sinus SCC.
- リンク情報
-
- DOI
- https://doi.org/10.1002/hed.25001
- PubMed
- https://www.ncbi.nlm.nih.gov/pubmed/29130565
- Scopus
- https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85033602725&origin=inward
- Scopus Citedby
- https://www.scopus.com/inward/citedby.uri?partnerID=HzOxMe3b&scp=85033602725&origin=inward
- URL
- http://orcid.org/0000-0002-4768-2358
- ID情報
-
- DOI : 10.1002/hed.25001
- ISSN : 1043-3074
- eISSN : 1097-0347
- ORCIDのPut Code : 46690427
- PubMed ID : 29130565
- SCOPUS ID : 85033602725